ABOUT
ORBITA

From bedside to dataset to guideline

Validated in world-leading clinical trials

Orbita Systems Ltd specializes in high-fidelity, app-based symptom tracking for clinical research and patient care. Born from the ground-breaking research at Imperial College London, our platform was developed to solve a critical problem in clinical trials: recall bias.

By enabling patients to log symptoms in real-time, we provide researchers and clinicians with a "symptom movie" rather than a snapshot. Our technology has been the digital backbone of major high-impact trials published in the New England Journal of Medicine and The Lancet, including ORBITA-2, SAMSON, ORBITA-FIRE, and ORBITA-STAR.

Focus on Data Quality

We replace retrospective questionnaires with real-time data capture. Our "Daily Symptom Counting" method has been proven to maximize data completeness and minimize the noise inherent in traditional recall-based assessments.

Focus on the Patient

Our app is designed for ease of use. In the ORBITA-2 trial, patients across a wide age range successfully reported symptoms daily for 12 weeks, demonstrating 99.7% data completeness.

Focus on the Science

We don't just build apps; we build evidence. Our platforms are rigorous scientific instruments, validated in placebo-controlled environments to ensure that the data you collect is data you can trust.

Focus on Insight

From quantifying angina episodes to tracking medication side effects (as in the SAMSON trial), our tools reveal the true burden of disease and the true efficacy of interventions.

A PROVEN TRACK RECORD

4

Major Landmark Trials

300+

Patients Randomized in ORBITA-2

>99%

Data Completeness

2

NEJM Publications

PUBLICATIONS & RECOGNITION

ORBITA-2 (NEJM, 2023)

"A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina." The Orbita app was the primary tool for data collection.

SAMSON (NEJM, 2020)

"N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects." Used our platform to track daily symptom scores.

ORBITA (The Lancet, 2018)

The foundational trial that established the methodology for blinded interventional cardiology trials.

ORBITA-STAR

Ongoing research expanding our digital follow-up technology to wider patient populations and new clinical questions.

:::

From Clinical Trials to Clinical Practice

The same rigorous tools used in ORBITA-2 are now available for clinical monitoring. We enable healthcare providers to monitor patient symptoms remotely, titrate medications effectively, and detect deterioration early. By bridging the gap between "bedside" and "dataset," we bring the precision of a clinical trial to everyday patient care.

:::

:::shared-card
#title
Scientific Leadership
#description
Our technology is driven by thought leaders in cardiology and clinical trial design. We are committed to transparency, open science, and the highest standards of evidence. We work with academic institutions, CROs, and device manufacturers to design modern trials that respect the patient experience while delivering unassailable data.
#link
:::app-link-button
---
to: /about/leadership
variant: outline
aria-label: "Meet our leadership"
---
Meet Leadership
:::
:::